buprenorphine transdermal / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 25 Diseases   17 Trials   17 Trials   675 News 


12345678910»
  • ||||||||||  buprenorphine transdermal / Generic mfg.
    Examining Social Determinates of Health in Adult Sickle Cell Disease Patients () -  Dec 7, 2024 - Abstract #ASH2024ASH_9712;    
    Future studies should track outpatient follow-up and readmission rates over time of this patient population. Additional goals will incorporate increased screening for depression, anxiety, stress of somatic complaints to improve referrals for care as well as increased use of buprenorphine transdermal patches over excessive oral opioid use with increased risk of mortality.This project was funded by the HRSA PCTE-RTMB grant.
  • ||||||||||  buprenorphine transdermal / Generic mfg.
    Journal:  Reliability of urine drug testing among patients on buprenorphine transdermal patch. (Pubmed Central) -  Dec 5, 2024   
    Additional goals will incorporate increased screening for depression, anxiety, stress of somatic complaints to improve referrals for care as well as increased use of buprenorphine transdermal patches over excessive oral opioid use with increased risk of mortality.This project was funded by the HRSA PCTE-RTMB grant. In addition to the UDT, a thorough history, screening for NMOU, physical exam, a review of PDMP, and a good understanding of opioid metabolism are necessary to help guide pain management.
  • ||||||||||  morphine sulphate / Generic mfg., buprenorphine transdermal / Generic mfg.
    Journal, Adverse events:  Long-term efficacy and reduced side-effects of buprenorphine in patients with moderate and severe chronic pain. (Pubmed Central) -  Aug 23, 2024   
    This retrospective study aimed to assess the long-term efficacy and safety of buprenorphine transdermal patches in patients with moderate and severe chronic pain, with a focus on pain relief sustainability and tolerance development...We evaluated changes in pain intensity using the Numeric Rating Scale (NRS), assessed opioid tolerance based on FDA guidelines for morphine-equivalent doses, and measured patient-reported outcomes through the Patients' Global Impression of Change (PGIC)...These results support the continued and expanded use of buprenorphine in clinical settings, emphasizing its role in reducing the burdens of chronic pain and opioid-related side effects. Further research is encouraged to refine pain management protocols and explore buprenorphine's full potential in diverse patient populations.
  • ||||||||||  buprenorphine transdermal / Generic mfg.
    Trial completion date, Trial primary completion date:  Kratom Use Disorder Management Using Clonidine and/or Buprenorphine (clinicaltrials.gov) -  May 14, 2024   
    P=N/A,  N=50, Recruiting, 
    Aim: Exploring prescribing trends and economic burden of chronic low back pain (cLBP) patients prescribed buprenorphine buccal film (Belbuca Trial primary completion date: Dec 2023 --> Dec 2024 | Trial completion date: Dec 2023 --> Dec 2024
  • ||||||||||  buprenorphine transdermal / Generic mfg.
    Trial completion date, Trial initiation date, Trial primary completion date:  Kratom Use Disorder Management Using Clonidine and/or Buprenorphine (clinicaltrials.gov) -  Oct 5, 2023   
    P=N/A,  N=50, Recruiting, 
    Fifty-six (56) patients scheduled for arthroplasty, received 7-day extended-release buprenorphine transdermal patches (5 Trial completion date: Aug 2023 --> Dec 2023 | Initiation date: Jul 2020 --> Jul 2018 | Trial primary completion date: Aug 2023 --> Dec 2023
  • ||||||||||  buprenorphine transdermal / Generic mfg.
    Preclinical, Journal:  In Vitro-In Vivo Correlation of Buprenorphine Transdermal Systems Under Normal and Elevated Skin Temperature. (Pubmed Central) -  May 7, 2023   
    The studies indicated that IVPT studies performed under the same conditions as those of interest in vivo may be useful for comparative evaluation of the effect of external heat on transdermal delivery system (TDS). Further research may be warranted to evaluate factors, beyond cutaneous bioavailability (BA) assessed using an IVPT study, that can influence plasma exposure in vivo for a given drug product.
  • ||||||||||  buprenorphine transdermal / Generic mfg.
    Trial completion date, Trial primary completion date:  Neuroimaging Study on the Effect of Transdermal Buprenorphine in Complex Regional Pain Syndrome Patients (clinicaltrials.gov) -  Apr 14, 2023   
    P=N/A,  N=20, Recruiting, 
    Further research may be warranted to evaluate factors, beyond cutaneous bioavailability (BA) assessed using an IVPT study, that can influence plasma exposure in vivo for a given drug product. Trial completion date: Apr 2022 --> May 2024 | Trial primary completion date: Feb 2021 --> Apr 2024
  • ||||||||||  Journal:  Opioids for pain. (Pubmed Central) -  Dec 22, 2022   
    Special caution is required during bee venom injection to avoid excessive doses of bee venom. No abstract available
  • ||||||||||  Sublocade (buprenorphine once-monthly depot) / Indivior
    Review, Journal:  Buprenorphine and its formulations: a comprehensive review. (Pubmed Central) -  Aug 25, 2022   
    Lastly, in order to avoid misuse of buprenorphine for opioid dependence, two combination formulations paired with naloxone were developed: film formulation (Suboxone®) and tablet formulation (Zubsolv®). In this review, we present details of each formulation along with their similarities and differences between each other and clinical considerations.
  • ||||||||||  buprenorphine transdermal / Generic mfg.
    Journal:  Application Site Reactions from the Buprenorphine Transdermal Patch: A Case Series. (Pubmed Central) -  May 6, 2022   
    The dose-response relationship and prolonged onset to ASR emergence may be suggestive of an allergic delayed hypersensitivity reaction. However, in this case series three subjects demonstrated tolerability to BBF either before or after developing a skin reaction to BTP.
  • ||||||||||  buprenorphine transdermal / Generic mfg.
    Retrospective data, Review, Journal:  Retrospective Review of the Use of Transdermal Buprenorphine Patches (Butrans) in a Pediatric Population. (Pubmed Central) -  Jun 22, 2021   
    Other studies have also demonstrated buprenorphine to be a safe and an effective opioid for the treatment of severe pain at the end of life in a pediatric population. Given these results, the implementation of buprenorphine in pediatrics may be safe for use in patients who are unable to tolerate traditional opioid analgesic therapies.
  • ||||||||||  The Changing Face of Buprenorphine: To Stop or Not to Stop? (Mezzanine 16AB) -  Jun 20, 2021 - Abstract #ASA2021ASA_2077;    
    Buprenorphine patch (Butrans®)?...Hydromorphone 1mg is bolused every 15 minutes with some decrease in blood pressure and heart rate...The fentanyl infusion is decided to be continued post-operatively for pain control as well as to prevent opioid withdrawal...Hypothetically, let's assume this patient was not on Suboxone® and instead received a naltrexone IM injection yesterday. 19) What are your concerns with a recent naltrexone injection versus after two weeks?20) What would be your concerns if this patient had a pre-existing subcutaneous naltrexone implant that was placed one month ago?
  • ||||||||||  The Changing Face of Buprenorphine: To Stop or Not to Stop? (Mezzanine 16AB) -  Jun 20, 2021 - Abstract #ASA2021ASA_801;    
    Buprenorphine patch (Butrans®)?...Hydromorphone 1mg is bolused every 15 minutes with some decrease in blood pressure and heart rate...The fentanyl infusion is decided to be continued post-operatively for pain control as well as to prevent opioid withdrawal...Hypothetically, let's assume this patient was not on Suboxone® and instead received a naltrexone IM injection yesterday. 19) What are your concerns with a recent naltrexone injection versus after two weeks?20) What would be your concerns if this patient had a pre-existing subcutaneous naltrexone implant that was placed one month ago?
  • ||||||||||  MoxDuo IR (morphine + oxycodone) / QRxPharma, AbbVie, Belbuca (buprenorphine BEMA) / BDSI, OxiFast (oxycodone immediate release) / Purdue, Shionogi, Mundipharma
    Journal:  Limited Access to On-Label Formulations of Buprenorphine for Chronic Pain as Compared with Conventional Opioids. (Pubmed Central) -  May 15, 2021   
    By substituting buprenorphine as the firstline treatment for chronic and even acute pain, there may be fewer prescribed conventional opioids in the United States. Schedule III buprenorphine formulations for chronic pain should be given unrestricted access for appropriate patients before considering a Schedule II opioid as a public health priority.